SPORE in Prostate Cancer

前列腺癌中的孢子

基本信息

批准号：
10478810
负责人：
Sarki A. Abdulkadir
金额：
$ 175.93万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-18 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10478810
关键词：
Advocacy Advocate Aggressive course American Antibody Therapy Antitumor Response Basic Science Bioinformatics Biology Biometry Biopsy Specimen Blood specimen Cancer Etiology Cancer Patient Catchment Area Chicago Clinical Clinical Sciences Clinical Trials Collaborations Combined Modality Therapy Comprehensive Cancer Center Core Facility DNA Damage Development Diagnosis Disease FDA approved Family member Focus Groups Friends Funding Genetic Transcription Health Health system Human Immune system Immunotherapy Infrastructure Innovative Therapy Institution Leadership MHC Class I Genes Malignant neoplasm of prostate Measurable Measures Mediating Metastatic Prostate Cancer Myelogenous National Cancer Institute Oncogenic PTEN gene Pathologist Pathway interactions Patient Care Patient-Focused Outcomes Patients Pharmacologic Substance Phase I Clinical Trials Phosphorylation Pre-Clinical Model Prostate specific antigen measurement Quality of life Regulation Research Research Personnel Research Project Grants Resistance STING agonists Scientist Signal Transduction Source Talents Testing Therapeutic Tissues Translating Translational Research Translations Treatment Efficacy Tumor-infiltrating immune cells Universities Visceral Work Yang anticancer research base bone c-myc Genes cancer genetics career castration resistant prostate cancer cohort design experience experimental study humanized monoclonal antibodies immune checkpoint blockade improved improved outcome inhibitor innovation investigator-initiated trial meetings member men mortality mouse model new technology novel novel strategies novel therapeutics patient population preclinical study programmed cell death protein 1 programs prostate cancer model recruit safety study success targeted treatment tumor tumor microenvironment tumor-immune system interactions

项目摘要

OVERALL: ABSTRACT This application is a request for renewal funding of the SPORE in Prostate Cancer P50 CA180995 at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in collaboration with the University of Chicago Comprehensive Cancer Center and NorthShore University HealthSystem, an affiliate of the University of Chicago. The SPORE first received support from the National Cancer Institute in 2001; a renewal application was funded in 2009. In 2015, we were the recipients of a new SPORE and we are now requesting continued funding for this program. Our SPORE unites basic scientists, clinicians, pathologists, biostatisticians, bioinformaticists and advocates from our academic institutions, all of whom are dedicated to advancing translational prostate cancer research. In this application we propose three highly translational and innovative research projects that have both basic science and clinical science co-leadership: Project 1: Targeting the MYC Pathway in Prostate Cancer (Abdulkadir, Hussain); Project 2: Re-directing the sensitivity of metastatic castration-resistant prostate cancer to immunotherapy (Wu, Sosman, Morgans); Project 3: STING Activation to Overcome Resistance to Immune Checkpoint Blockade in PTEN-deficient Prostate Cancer (Patnaik, Gajewski, Stadler). Three core facilities support the proposed research projects: Administrative, Leadership and Advocacy (Abdulkadir, Hussain, Stadler); Biostatistics/Bioinformatics (Kocherginsky, Zhao) and Biospecimen (Yang). Internal and External Advisory Boards provide a source of scientific input to members of the SPORE team on a biannual and yearly basis, respectively. Our Advocacy Group are well established in the SPORE arena and make a valued contribution to our success. The SPORE includes Developmental Research and Career Enhancement Programs, both of which provide a source of innovation and new discoveries. All together, we anticipate that the results obtained from our research endeavors will have a significant impact on the health of patients diagnosed with prostate cancer.

总体：摘要该申请是在罗伯特（Robert H. Lurie与芝加哥大学合作的西北大学综合癌症中心综合癌症中心和北岸大学健康系统，大学的分支机构芝加哥。孢子于2001年首次获得国家癌症研究所的支持；续订申请成立于2009年。2015年，我们是新孢子的接受者，现在我们要求继续该计划的资金。我们的孢子团结了基础科学家，临床医生，病理学家，生物统计学家，我们的学术机构的生物信息学家和倡导者都致力于晋升转化前列腺癌研究。在此应用程序中，我们提出了三个高度转化和创新的具有基础科学和临床科学共同领导的研究项目：项目1：针对MYC 前列腺癌（Abdulkadir，Hussain）的途径；项目2：重新指导转移性的灵敏度耐受性前列腺癌对免疫疗法（Wu，Sosman，Morgans）；项目3：激活克服对PTEN缺乏的前列腺癌中免疫检查点阻滞的抵抗力（Patnaik，Gajewski， Stadler）。三个核心设施支持拟议的研究项目：行政，领导和倡导（Abdulkadir，Hussain，Stadler）；生物统计学/生物信息学（Kocherginsky，Zhao）和Biospecimen（Yang）。内部和外部咨询委员会为孢子团队成员提供了科学意见的来源双年度和每年的基础。我们的倡导小组在孢子竞技场和为我们的成功做出重要的贡献。孢子包括发展研究和职业增强计划，两者都提供了创新和新发现的来源。我们在一起，我们预计从我们的研究努力中获得的结果将对诊断为前列腺癌的患者。